Arcturus Therapeutics Holdings

Traded on the St. Petersburg Stock Exchange
Arcturus Therapeutics is an American biotech company focused on the discovery, development and commercialization of therapeutics for rare diseases with focus on RNA. Arcturus has developed a RNA therapeutics platform called LUNAR, a proprietary lipid-enabled delivery system for RNA medicines. The company was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Arcturus Therapeutics Holdings balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Arcturus Therapeutics Holdings cash flows

Report period2019 2020 2021 2022 2023 Q2 24 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Arcturus Therapeutics Holdings multipliers

Report period2019 2020 2021 2022 2023 Q2 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Arcturus Therapeutics Holdings profitability

Report period2019 2020 2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Arcturus Therapeutics Holdings assets
Arcturus Therapeutics Holdings cash flows

Arcturus Therapeutics Holdings dividend policy

The company doesn't provide dividend

Arcturus Therapeutics Holdings shares

TickerNameTypeNominal valueISINPrice
ARCT:USArcturus Therapeutics HoldingsCommon share-US03969T1097$16.94
Arcturus Therapeutics Holdings news
10.05.2022
Arcturus Therapeutics Holdings reported a GAAP loss of $51.169 million for the 3 months of 2022, down 9.2% from $56.346 million in the prior year. Revenue increased 2.5 times to $5.244 million from $2.127 million a year earlier.
01.03.2022
Arcturus Therapeutics' GAAP loss in Q4 2021 was $38.664 million, up 24.3% from $31.104 million in the prior year. Revenue increased 2.6-fold to $5.794 million compared to $2.238 million a year earlier.
09.11.2021
Arcturus Therapeutics Holdings' GAAP loss in Q3 2021 was $54.084 million, up 2.6 times from $21.004 million in the previous year. Revenue increased 4.5% to $2.437 million from $2.333 million a year earlier.
09.08.2021
Arcturus Therapeutics Holdings' GAAP loss in Q2 2021 was $54.581 million, up 5.3 times from $10.263 million in the prior year. Revenue decreased 13.8% to $2,001 million from $2,322 million a year earlier.
General information
Company nameArcturus Therapeutics Holdings
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address10628 Science Center Drive San Diego, CA 92121 United States
Mailing address10628 Science Center Drive San Diego, CA 92121 United States
Websiteir.arcturusrx.com
Information disclosurewww.sec.gov